SARS News and Research

RSS

Smartphone mobility tracking strongly predicts COVID-19 outbreaks

Mobility tracking using cell phone data showing greater movement of people is a strong predictor of increased rates of COVID-19, according to new data in CMAJ (Canadian Medical Association Journal)

8 Apr 2021

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

Eight months after mild COVID-19, one in ten people still has at least one moderate to severe symptom that is perceived as having a negative impact on their work, social or home life. The most common long-term symptoms are a loss of smell and taste and fatigue.

8 Apr 2021

The interaction between blood clotting and SARS-CoV-2 infection

Coagulopathy - a condition in which the blood's ability to clot is impaired, is recognized as a significant aspect of morbidity in COVID-19 patients. In a recent study, Prof Lewis Cantley and a team of researchers explored the role of coagulation factors in the SARS-CoV-2 infection. Their recent study is posted on the bioRxiv server.

7 Apr 2021

Real-world proof Pfizer and Moderna mRNA vaccines prevent SARS-CoV-2 infection

A new Morbidity and Mortality Weekly Report published by the U.S. Centers for Disease Control and Prevention (CDC) states that mRNA COVID-19 vaccines are highly effective in preventing SARS-CoV-2 infection in the real world. The report is based on a CDC study where it routinely tested prospective cohorts of health care professionals, first responders, and essential and frontline workers for SARS-CoV-2 infections.

7 Apr 2021

Bispecific antibodies neutralize SARS-CoV-2 and its variants

A new bioRxiv preprint study led by Joshua Tan from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, involves generating bispecific antibodies using a new method cross-linking the antibodies with adjacent spike proteins using dual N-terminal domain/receptor binding domain specificity.

7 Apr 2021

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

Makdasi et al. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants. bioRxiv, 2021. doi: https://doi.org/10.1101/2021.04.01.438035, https://www.biorxiv.org/content/10.1101/2021.04.01.438035v2

7 Apr 2021

COVID-19 antibodies persist in breast milk for months following mother’s vaccination

Nursing mothers who receive a COVID-19 vaccine may pass protective antibodies to their babies through breast milk for at least 80 days following vaccination, suggests new research from Washington University School of Medicine in St. Louis.

7 Apr 2021

Michigan Medicine to kick off first national study on allergic reactions to COVID-19 vaccines

In a carefully controlled study, Michigan Medicine researchers will kick off the first national trial to study allergic reactions to the COVID-19 mRNA vaccines.

7 Apr 2021

NIH-funded clinical trial begins study of systemic allergic reactions to COVID-19 vaccines

A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines.

7 Apr 2021

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

A team of scientists from the University of California Santa Cruz, USA, recently identified a novel variant (B.1.x) of SARS-CoV-2 that might be circulating in at least 20 US states and six countries globally.

7 Apr 2021

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

A promising new study reports on the high neutralizing efficacy of a polyclonal swine antibody against SARS-CoV-2, the pathogen responsible for the novel COVID-19. By demonstrating the ability of this antibody to neutralize all currently circulating viral variants, the study suggests that it is ideal for development as a new and very effective therapy for COVID-19.

7 Apr 2021

Which SARS-CoV-2 spike mutants can evade T cell immunity?

A new study reports the capability of a new variant of the virus to escape specific cellular immunity, while possessing a higher binding affinity to the host cell binding receptor, the angiotensin-converting enzyme 2 (ACE2).

7 Apr 2021

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

A new study describes the use of a single dose of vaccine based on the viral protein called the receptor-binding domain (RBD) to elicit powerful neutralizing activity against both the Wuhan strain and the most concerning VOC called the South African (SA) strain.

7 Apr 2021

Global secretive governments are bypassing rules during COVID-19 pandemic

From Brazil to the Philippines, secretive governments across the world are responding to the COVID-19 pandemic by covering up data and bypassing public procurement rules, undermining trust in health systems, fuelling anti-vaxxers and putting immunisation campaigns at risk.

7 Apr 2021

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

Researchers at the Infection Biology Unit, German Primate Center, and the Georg-August-University Göttingen in Germany have found that the B.1.351 and P.1 SARS-CoV-2 variants have the potential to evade therapeutic antibodies or antibodies induced by natural infection or vaccination.

7 Apr 2021

UNION therapeutics’ COVID-19 candidates show promising results in phase 1 study

UNION therapeutics A/S (UNION) announced today that the results of a phase 1 study of inhaled and intranasal niclosamide (UNI911) have been published by The Lancet Regional Health – Europe.

7 Apr 2021

Researchers use South Korea Data to create new framework for COVID-19-vulnerable locales

Though the U.S. and South Korea recorded their first official COVID-19 case on the same day, January 20, 2020, there were notable differences in how each country would ultimately address what has become the world's most severe pandemic since 1918.

7 Apr 2021

Antifungal and antidepressant drugs can effectively inhibit COVID-19 virus

New research published in the British Journal of Pharmacology indicates that two currently available medications--an antifungal drug and an antidepressant--can effectively inhibit the virus that causes COVID-19 in laboratory cells.

7 Apr 2021

Expert calls for swift action to avoid chronic health conditions caused by COVID-19

A tsunami of chronic health conditions as a result of the SARS-CoV-2 pandemic, especially cardiometabolic disease, may produce an enormous wave of death and disability that demands immediate, comprehensive strategies.

7 Apr 2021

70% of SARS-CoV-2 infected in Wuhan still have IgG antibodies

The coronavirus disease (COVID-19) first emerged in late December 2019 in Wuhan, China. Though it has been more than one year since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported, it is still unclear how long the antibodies persist in those who have recovered.

7 Apr 2021

SARS News and Research

Smartphone mobility tracking strongly predicts COVID-19 outbreaks

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

The interaction between blood clotting and SARS-CoV-2 infection

Real-world proof Pfizer and Moderna mRNA vaccines prevent SARS-CoV-2 infection

Bispecific antibodies neutralize SARS-CoV-2 and its variants

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

COVID-19 antibodies persist in breast milk for months following mother’s vaccination

Michigan Medicine to kick off first national study on allergic reactions to COVID-19 vaccines

NIH-funded clinical trial begins study of systemic allergic reactions to COVID-19 vaccines

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

Which SARS-CoV-2 spike mutants can evade T cell immunity?

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

Global secretive governments are bypassing rules during COVID-19 pandemic

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

UNION therapeutics’ COVID-19 candidates show promising results in phase 1 study

Researchers use South Korea Data to create new framework for COVID-19-vulnerable locales

Antifungal and antidepressant drugs can effectively inhibit COVID-19 virus

Expert calls for swift action to avoid chronic health conditions caused by COVID-19

70% of SARS-CoV-2 infected in Wuhan still have IgG antibodies

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News